spacer
home > ict > autumn 2016 > communication is key
PUBLICATIONS
International Clinical Trials

Communication is Key

ICT: This year’s spotlight at the Partnerships in Clinical Trials (PCT) Europe event is on patient centricity. In your opinion, what are the main challenges in recruiting and retaining subjects today, and what can be done to improve this often labour-intensive and costly task?

Naomi Brooker: While researching with industry professionals, it appears that one of the fundamental issues lies within how we are communicating – patients don’t want to feel like guinea pigs that are being experimented on. The general public perception is that clinical trials can be risky, and this can be off-putting; after all, they generally only see the disasters in the news, not the many success stories that arise from trials. In particular, some patients worry that they could be given a placebo that could be detrimental to their health, while others are concerned that companies are more interested in profit than helping them recover; others decided that the risk factor was too great.

To remove this underlying fear, communication is key and marketing campaigns, as well as patient advocates, can play a pivotal role. What are you, as a company, doing to ensure that patients feel valued? How are they engaged with? Are they treated as a number or a person? These are the real questions that can make a difference.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Naomi Brooker is the Conference Director of PCT Europe, developing the event in partnership with their advisory board. Since completing a BSc at UCL, UK, in Biomedical Science and a Law Conversion at BBP Law School, UK, she has been researching key trends and current challenges with various industry sectors such as pharma and agrochemical, most recently focusing on clinical trials.
spacer
Naomi Brooker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Evonetix Appoints Colin McCracken as Chief Executive Officer

Cambridge, UK, 13 June 2022: EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement